Curatis valuation report: Epidemiology data reveal vast potential

Monday, November 24, 2025 @ 12:00 am

Longer BLA exclusivity prompted an expansion of corticorelin development from a small group of children to all children and adults with PTBE in brain tumors. US data indicate approx. 96,000 metastatic brain cancer patients with PTBE. A deal is expected in 2026, with a phase 3 trial set for Q1 2027. Peak sales doubled to CHF 2+ bn.

Key catalysts include:

1. Cortecorelin - Partnering agreement (2026)
2. C-AM-01 - Finalize phase IIb-readiness (2026/2027)
3. Corticorelin - Start phase 3 trial (Q1 2027)

Curation Valuation Report

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

BC Platforms launches first-to-market AI-native analytics product that accelerates precision medicine

Proprietary agentic AI model transforms genomic and real-world data into actionable insights across the full drug lifecycle Enables faster development of breakthrough therapies, including tumor-agnostic cancer treatments, through a 360-degree view of the precision medicine landscape Empowers scientific researchers across the life sciences and healthcare continuum to perform large-scale data analys
November 18, 2025

Pharvaris: Third quarter 2025 financial results

Topline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, expected in 4Q2025 Enrollment in CHAPTER-3, a pivotal Phase 3 study of deucrictibant extended-release tablet for prophylaxis of HAE attacks, is progressing as planned; topline data anticipated in 2H2026 Initiated CREAATE, a pivotal Phase 3 study of deucrictibant
November 12, 2025

Molecular Partners: First human images from targeting radiotherapy

Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-DARPin leverages rapid internalization & replenishment of DLL3 to achieve high accumulation in tumor cells Phase 1 IND for MP0712 filed, clinical trial initiation expected before end-2025 in US with initial data expected in 2
November 12, 2025

InSphero acquires DOPPL SA for 3D in vitro drug models

InSphero AG is acquiring DOPPL SA to create the most comprehensive 3D in vitro model portfolio, combining scalable spheroid and organoid technologies for next-generation drug discovery and safety testing.
November 11, 2025

Oculis: Oversubscribed USD 110 million financing for neuroprotective clinical candidate

Oculis Holding AG (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.25 per share for total gross proceeds of $1
October 30, 2025